146: Use of a novel organic arsenic (ZIO-101) after autotransplants for multiple myeloma
Mohamed Hussein, James Berenson(Institute for Myeloma & Bone Cancer Research), Lawrence Boise(Emory University), Brian Schwartz(Cyclacel Pharmaceuticals (United Kingdom)), Andrew R. Belch, R. P. Gale(Cleveland Clinic), Bart Barlogie(University of Arkansas for Medical Sciences), Ralph V. Boccia(Center for Cancer and Blood Disorders), Richard A. Campbell(Institute for Myeloma & Bone Cancer Research)
Cited by 1
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
|Blood|2006|1.1k